Efficacy of amitraz plus inactivated parapoxvirus ovis in the treatment of canine generalised demodicosis

2014 ◽  
Vol 174 (22) ◽  
pp. 556-556 ◽  
Author(s):  
D. Pekmezci ◽  
G. Z. Pekmezci ◽  
M. Guzel ◽  
S. Cenesiz ◽  
A. T. Gurler ◽  
...  
2017 ◽  
Vol 08 (05) ◽  
Author(s):  
H Von Buttlar ◽  
M Protschka ◽  
M Muhsen ◽  
G Köhler ◽  
H Lang ◽  
...  

Author(s):  
M. Pohlscheidt ◽  
U. Langer ◽  
B. Bödeker ◽  
D. Paulsen ◽  
H. Rübsamen-Waigmann ◽  
...  

2019 ◽  
Vol 7 (3) ◽  
pp. e000898 ◽  
Author(s):  
Amanda Burke ◽  
Jack Kottwitz ◽  
Chengming Wang ◽  
Amelia White

A six-year-old spayed female silver fox (Vulpes vulpes) presented with bilateral ocular discharge, lethargy, facial alopecia and dermatitis of six months’ duration. The fox was immobilised with ketamine (4 mg/kg), dexmedetomidine (0.01 mg/kg) and butorphanol (0.05 mg/kg) intramuscularly for skin cytology, skin scrapings, dermatophyte culture, bloodwork, faecal floatation and skin biopsies. Diagnostics revealed numerous Demodex species mites. Histopathology showed folliculitis, perifolliculitis and furunculosis with mites, identified as Demodex canis using RT-PCR. The fox received meloxicam (0.2 mg/kg by mouth, three days), cefovecin (8.6 mg/kg subcutaneously, single injection), praziquantel (56.8 mg, subcutaneously, single injection), and fluralaner (250 mg, by mouth, once every 12 weeks, Bravecto). Complete resolution was noted one month after initiating treatment. Thirteen months later the fox remains mite-free and is receiving fluralaner by mouth every 12 weeks. This case report describes successful management of adult-onset generalised Demodex species dermatitis in a silver fox using oral fluralaner.


2010 ◽  
Vol 140 (1-2) ◽  
pp. 81-91 ◽  
Author(s):  
Nicole Schütze ◽  
Rüdiger Raue ◽  
Mathias Büttner ◽  
Gabriele Köhler ◽  
Colin J. McInnes ◽  
...  

2011 ◽  
Vol 92 (7) ◽  
pp. 1571-1584 ◽  
Author(s):  
Astrid Friebe ◽  
Sonja Friederichs ◽  
Kai Scholz ◽  
Uwe Janssen ◽  
Corinna Scholz ◽  
...  

Inactivated orf virus (ORFV, parapoxvirus ovis) induces antiviral activity in animal models of acute and chronic viral infections and exerts strong effects on human immune cells. ORFV activates antigen presenting cells (APC) via CD14 and, probably, Toll-like receptor signalling, and triggers the release of IFN-γ that has been identified as the key mediator of the antiviral activity. After delineating virus proteins as being the most likely active constituent, we aimed to characterize the ORFV proteins responsible for the therapeutic effect. By using a vaccinia virus/ORFV expression library we identified several multi-gene DNA fragments with strong immunomodulatory activity. Together these fragments contain 27 ORFs. The encoded proteins are related to virion structure and transcription but are otherwise unrelated. Two proteins were separately expressed and purified, and demonstrated immunostimulatory activity. Gene expression profiles induced by ORFV and the identified fragments were investigated by microarray analysis. Interestingly, all active fragments induced a similar gene-expression pattern, differing only in quantitative aspects. Obviously, several proteins of ORFV activate similar cellular pathways, modulating APC to generate a strong T-helper 1-dominated immune response. This was balanced by additional induction of immune dampening mechanisms, suggesting regulatory differences compared to single cytokine therapies. We conclude that ORFV may have the potential to enrich the armamentarium of antiviral therapies.


2016 ◽  
Vol 88 (3) ◽  
pp. 1451-1457
Author(s):  
TATIANA R. PAVAN ◽  
CRISTIAN O. NIED ◽  
MIRELA NORO ◽  
DENIZ ANZILIERO ◽  
RAFAEL FRANDOLOSO ◽  
...  

2001 ◽  
Vol 75 (10) ◽  
pp. 4699-4704 ◽  
Author(s):  
Nicole Kruse ◽  
Olaf Weber

ABSTRACT Viruses have evolved numerous mechanisms to avoid host immune reactions. Here we report a mechanism by which Parapoxvirus ovis (PPVO) interferes with antigen presentation. PPVO (orf virus) causes orf, an acute skin disease of sheep and goats worldwide. Importantly, PPVO can repeatedly infect its host in spite of a vigorous inflammatory and host immune response to the infection. We demonstrate in a mouse system that PPVO induces apoptosis in a significant number of antigen-presenting cells after intraperitoneal injection using the CD95 pathway, thus preventing a primary T-cell response. We also show that PPVO induces a compensatory activation of the immune system. Our results may help to explain the phenomenon that natural PPVO infections in sheep occur repeatedly even after short intervals. They also suggest that the combination of immunosuppressive and immunostimulatory mechanisms is an effective survival strategy that might be used in other viruses as well.


2019 ◽  
Vol 4 (2) ◽  
Author(s):  
Sarah Long

<p><strong>PICO question</strong></p><p>In dogs with generalised demodicosis, are isoxazolines as effective as a combined formulation of imidacloprid and moxidectin at reducing mite count and the severity of associated clinical signs?</p><p><strong>Clinical bottom line</strong></p><p>Five single-blinded, randomised, positive control trials, most under laboratory conditions, directly compared the use of isoxazolines against moxidectin/imidacloprid to treat canine generalised demodicosis. All of them showed comparable efficacy of isoxazolines. Three different isoxazolines were studied with two routes of administration (oral and topical) and four different dosing frequencies of moxidectin/imidacloprid. This made the papers more challenging to compare however, the evidence provided is sufficient to support their use. All of these trials were sponsored by the manufacturers of their respective isoxazoline products which may bias the study design and reporting of results. It is worth noting that sarolaner (Simparica™, Zoetis UK) was licensed in the UK for the treatment of canine demodicosis in January 2018 and that in the UK the Cascade should be followed when prescribing treatments. The licensed use of isoxazolines in other countries is beyond the scope of this article and the reader is urged to check local regulatory body advice before prescribing the below medications.</p><br /> <img src="https://www.veterinaryevidence.org/rcvskmod/icons/oa-icon.jpg" alt="Open Access" /> <img src="https://www.veterinaryevidence.org/rcvskmod/icons/pr-icon.jpg" alt="Peer Reviewed" />


Sign in / Sign up

Export Citation Format

Share Document